Saffron

Updated June 29, 2026

Saffron is the dried stigmas of Crocus sativus, a flowering plant cultivated for over 3,500 years primarily in Iran, which produces roughly 90 percent of the world’s supply. It is the world’s most expensive spice by weight, a consequence of the labour-intensive hand-harvesting of three stigmas per flower. The primary bioactive compounds are crocin and crocetin (carotenoid pigments responsible for saffron’s distinctive golden colour), safranal (the volatile compound responsible for its aroma), and picrocrocin (which contributes bitterness). These compounds act through distinct mechanisms, giving saffron an unusually broad pharmacological profile for a plant-derived supplement.

The mood evidence is the most compelling and the most studied. Multiple double-blind randomised controlled trials have compared 30 mg per day of saffron extract to low-dose antidepressants — fluoxetine, imipramine, and citalopram — and found non-inferior efficacy for mild to moderate depression over 6 to 8 weeks. A 2013 meta-analysis of five trials confirmed this finding across different populations and preparations. The proposed mechanisms are serotonin reuptake inhibition (crocin weakly inhibits SERT), monoamine oxidase inhibition by safranal, and direct modulation of NMDA receptors and GABA-A receptors. The combination of these weak, multi-target mechanisms appears to produce a clinically meaningful effect with substantially fewer side effects than pharmaceutical antidepressants — no sexual dysfunction, no significant weight gain, and minimal discontinuation symptoms.

Eye health is the second major evidence base. Crocin and crocetin are carotenoids that accumulate in retinal tissue and protect photoreceptors against oxidative stress and light-induced damage. In a series of controlled trials by Silvia Bisti’s group at the University of L’Aquila, 20 mg per day of saffron extract significantly improved retinal function in early age-related macular degeneration (AMD) — as measured by ERG (electroretinography) — within three months, with sustained improvement at 15 months. A subsequent Australian trial confirmed improved macular function in AMD patients. Given the limited pharmacological options for early AMD and the safety profile of saffron, this is a standout finding. The mechanism involves both direct antioxidant protection of photoreceptor outer segments and support for the RPE (retinal pigment epithelium) cells that maintain them.

Appetite and weight management effects are consistent across several trials. Saffron supplementation reduces snacking frequency, decreases caloric intake, and blunts cravings — particularly hedonic eating driven by stress or boredom rather than hunger. The mechanism is primarily serotonergic: elevated serotonin availability in the hypothalamus and limbic system increases satiety signalling and reduces reward-driven eating. A double-blind trial using 176.5 mg of a specific saffron extract (Satiereal) showed a 55 percent reduction in snacking episodes over 8 weeks compared to placebo. This effect complements the mood benefit, as low mood and emotional eating frequently co-occur.

Cognitive benefits are emerging. Animal studies show saffron improves spatial memory and learning, and small human trials in Alzheimer’s patients show cognitive improvement comparable to low-dose donepezil over 22 weeks. Crocin specifically inhibits acetylcholinesterase (the enzyme that degrades acetylcholine) and reduces amyloid-beta aggregation in vitro. These findings position saffron as a genuine candidate for cognitive ageing support, though large-scale human trials are still needed.

The standard dose is 30 mg per day of a standardised extract, split into two 15 mg doses or taken once daily. Cooking quantities used as a spice are far lower than supplemental doses and unlikely to produce measurable pharmacological effects. Quality matters considerably — standardisation to crocin content (typically 2 percent or higher) ensures consistent potency. Saffron is well tolerated at standard doses; at very high doses (above 5 grams total, far exceeding supplement levels) it has emmenagogue and uterine-stimulant properties, making it one to avoid at high doses during pregnancy. At 30 mg supplemental doses, no safety concerns have emerged in the published trial record. This is general information, not medical advice.